The alternative text for this image may have been generated using AI. Several RAF inhibitors are in clinical trials, but three recently published papers indicate that the function of the RAS pathway ...
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today announced ...
Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC). This is an ...
Ikena Oncology Inc. has nominated a next-generation mitogen-activated protein kinase (MEK)-RAF complex inhibitor, IK-595, as the company's first development candidate in the RAS pathway. IK-595 traps ...
Morphologic and genomic characterization of circulating tumor cells in patients with metastatic colorectal cancer treated with combinational treatment of andecaliximab, bevacizumab and chemotherapy.
Figure 1: Key signaling pathways and targeted factors in dysregulated BC. This figure illustrates the major signaling pathways and their intricate crosstalk in BC, focusing on the GPCR, RTKs, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results